Literature DB >> 19212932

[Kidney procurement and transplantation from a surgical perspective].

M Heuer1, N R Frühauf, J Treckmann, O Witzke, A Paul, G M Kaiser.   

Abstract

Kidney transplantation is the best therapeutic option in many patients with end-stage renal disease, because it significantly increases lifespan over that of patients who remain on dialysis. Because of organ shortage the average waiting time for a suitable kidney in Germany is about four years after the onset of dialysis treatment. Currently about 80% of all transplanted kidneys are obtained from brain-dead patients. The possibility for kidney transplantation after living donation reduces the minimum waiting time to a few weeks. An optimized organizational strategy as well as donor and recipient preparation are possible in living donation, resulting in excellent transplant quality and a short cold-ischemia time. Pre-emptive kidney transplantation after living donation is an attractive treatment option without the need for previous dialysis and is also an option for children. The excellent long-term results after kidney transplantation have been caused by improvement of operative technique, organizational strategy, donor preparation, postoperative care and, in particular, immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212932     DOI: 10.1055/s-0028-1124009

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  [Kidney injury and multiple trauma: outcome, course and treatment algorithm. An organ-specific evaluation of 835 patients from the trauma register of the DGU].

Authors:  M Heuer; B Hussmann; M Schenck; D Nast-Kolb; S Ruchholtz; R Lefering; A Paul; G Taeger; S Lendemans
Journal:  Unfallchirurg       Date:  2012-08       Impact factor: 1.000

2.  Use of marginal organs in kidney transplantation for marginal recipients: too close to the margins of safety?

Authors:  M Heuer; A Zeiger; G M Kaiser; Z Mathé; A Goldenberg; S Sauerland; A Paul; Jürgen W Treckmann
Journal:  Eur J Med Res       Date:  2010-01-29       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.